Belgian T reg specialist Dualyx NV had raised €40m to progress its three preclinical Treg candidates for autoimmune diseases into the clinic.
NHS research partners of AstraZeneca and Sanofi have reported a 83% reduction in RSV infant hospitalisations in a post-approval clinical trial.
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
French pancreatic beta-cell modulator specialist DiogenX SA has raised €27.5m in a Series A financing led by Boehringer Ingelheim Venture Fund and Roche Venture Fund.
Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
German Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.
The European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.